60MO Real-world overall and progression-free survival for first-line immunotherapy-based regimens in advanced non-small cell lung cancer
| Autor: | Waterhouse, D.M., Ray, S., Betts, K.A., Yuan, Y., Yin, L., Gao, S., Sundar, M., Stenehjem, D. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|